Raven StealthCo- Director, Oligonucleotide and Conjugation Chemistry

About Raven

We are Raven, RA Capital’s healthcare incubator. From discovery to delivery, whether we incubate, accelerate or rejuvenate, Raven’s goal is to turn scientific breakthroughs into transformative therapies and get them quickly, safely and efficiently to the patients that need them most. Raven’s experienced scientists, operators, and healthcare innovators have deep sector expertise across therapeutics, diagnostics, devices and services. They have brought hundreds of therapeutics into development, managed hospital systems, optimized clinical trials and navigated payor and regulatory systems to deliver patient impact - and they are ready to work with you.

Founded in 2004, RA Capital Management is a multi‑stage investment manager dedicated to evidence‑based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow‑on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital’s knowledge engine is guided by our Tech Atlas internal research division, and Raven, RA Capital’s company building team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re‑imagined.

RA Capital has more than 150 employees and over $10 billion in assets under management.

We are a well‑funded, stealth‑mode biotechnology focused on next generation oligo‑based modalities targeting tissues beyond the liver, muscle, and kidney. We are building a platform to deliver oligos with high precision to previously untargeted cells, while focused on “undruggable” genes, alone or in combination with previously validated targets. Many of our targets carry “pipeline‑in‑a‑drug” potential: a single gene or protein with meaningful biological effects across multiple disease areas.

Headquartered in Cambridge, Massachusetts, the company was incubated in RA Capital’s venture group (Raven) and is led by an experienced CEO. After a robust incubation and vetting process, Raven Stealth Co was launched and funded by RA Capital. The company’s therapeutic areas of interest lie outside commonly targeted cells and tissues, and represent multi‑billion‑dollar markets that are continuing to grow as the population ages.

Our initial focus is creating transformational therapies to treat diseases, but given the platform potential, we have longer‑term ambitions to address healthy aging. These targets are backed by strong biological and genetic evidence but have historically resisted small molecule and biologic approaches. Raven Stealth Co is moving quickly to address multiple disease indications at scale and with significant market potential.

We are in the discovery stage and will invest heavily in its emerging platform for oligonucleotide delivery. Our disease focus offers strong translatability from animal models to humans, which provides a potentially rapid and efficient path to the clinic. Given our recent funding and commitment to building a first‑in‑class platform with clear therapeutic targets and indications, we are recruiting a Director, Oligonucleotide and Conjugation Chemistry.

This individual will be responsible for implementing chemical technologies to develop oligonucleotides and conjugates for our targeted delivery platform.

The Director, Oligonucleotide and Conjugation Chemistry will report directly to the VP of Delivery and will interface frequently with company leadership and cross‑functional teams to advance oligonucleotide therapeutic programs. This individual will contribute to strategy and execution of discovering novel delivery systems and will manage chemistry resources to prepare oligonucleotide conjugates. This individual will be expected to interact frequently with external CROs as well as recruit, mentor, and manage a skilled scientific team under their leadership.

• Oversee chemistry aspects of the development of oligonucleotide conjugates for biological evaluation in our targeted delivery platform
• Manage…